151 related articles for article (PubMed ID: 12881310)
21. Structural basis of interaction between urokinase-type plasminogen activator and its receptor.
Barinka C; Parry G; Callahan J; Shaw DE; Kuo A; Bdeir K; Cines DB; Mazar A; Lubkowski J
J Mol Biol; 2006 Oct; 363(2):482-95. PubMed ID: 16979660
[TBL] [Abstract][Full Text] [Related]
22. Regulation of single chain urokinase binding, internalization, and degradation by a plasminogen activator inhibitor 1-derived peptide.
Zhang L; Strickland DK; Cines DB; Higazi AA
J Biol Chem; 1997 Oct; 272(43):27053-7. PubMed ID: 9341144
[TBL] [Abstract][Full Text] [Related]
23. Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization.
Sidenius N; Andolfo A; Fesce R; Blasi F
J Biol Chem; 2002 Aug; 277(31):27982-90. PubMed ID: 12034711
[TBL] [Abstract][Full Text] [Related]
24. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
[TBL] [Abstract][Full Text] [Related]
25. Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction.
Ploug M; Rahbek-Nielsen H; Ellis V; Roepstorff P; Danø K
Biochemistry; 1995 Oct; 34(39):12524-34. PubMed ID: 7548000
[TBL] [Abstract][Full Text] [Related]
26. Novel interactions between urokinase and its receptor.
Shliom O; Huang M; Sachais B; Kuo A; Weisel JW; Nagaswami C; Nassar T; Bdeir K; Hiss E; Gawlak S; Harris S; Mazar A; Higazi AA
J Biol Chem; 2000 Aug; 275(32):24304-12. PubMed ID: 10801829
[TBL] [Abstract][Full Text] [Related]
27. Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain.
Kim KS; Hong YK; Lee Y; Shin JY; Chang SI; Chung SI; Joe Y
Exp Mol Med; 2003 Dec; 35(6):578-85. PubMed ID: 14749538
[TBL] [Abstract][Full Text] [Related]
28. Potential role of kringle-integrin interaction in plasmin and uPA actions (a hypothesis).
Takada Y
J Biomed Biotechnol; 2012; 2012():136302. PubMed ID: 23125522
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the ternary complex formation of human urokinase with the separated two domains of its receptor.
Oda M; Shiraishi A; Hasegawa M
Eur J Biochem; 1998 Sep; 256(2):411-8. PubMed ID: 9760182
[TBL] [Abstract][Full Text] [Related]
30. Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143).
Huang M; Mazar AP; Parry G; Higazi AA; Kuo A; Cines DB
Acta Crystallogr D Biol Crystallogr; 2005 Jun; 61(Pt 6):697-700. PubMed ID: 15930623
[TBL] [Abstract][Full Text] [Related]
31. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
Ploug M
Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416
[TBL] [Abstract][Full Text] [Related]
32. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
Ploug M; Ostergaard S; Hansen LB; Holm A; Danø K
Biochemistry; 1998 Mar; 37(11):3612-22. PubMed ID: 9521680
[TBL] [Abstract][Full Text] [Related]
33. Heparin binding to the urokinase kringle domain.
Stephens RW; Bokman AM; Myöhänen HT; Reisberg T; Tapiovaara H; Pedersen N; Grøndahl-Hansen J; Llinás M; Vaheri A
Biochemistry; 1992 Aug; 31(33):7572-9. PubMed ID: 1510944
[TBL] [Abstract][Full Text] [Related]
34. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction.
Høyer-Hansen G; Behrendt N; Ploug M; Danø K; Preissner KT
FEBS Lett; 1997 Dec; 420(1):79-85. PubMed ID: 9450554
[TBL] [Abstract][Full Text] [Related]
35. Domain interplay in the urokinase receptor. Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains.
Behrendt N; Ronne E; Dano K
J Biol Chem; 1996 Sep; 271(37):22885-94. PubMed ID: 8798468
[TBL] [Abstract][Full Text] [Related]
36. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
Ballance DJ; Marshall JM; Cottingham IR; Steven J; Berry SJ; Cederholm-Williams SA; Goodey AR; Courtney M
Eur J Biochem; 1992 Jul; 207(1):177-83. PubMed ID: 1321039
[TBL] [Abstract][Full Text] [Related]
37. Unesterified long chain fatty acids inhibit the binding of single chain urokinase to the urokinase receptor.
al-Roof Higazi A; Aceto JF; Kniss D; Upson R; Cohen R; Dichek DA; Cines DB
Biochemistry; 1996 May; 35(21):6884-90. PubMed ID: 8639640
[TBL] [Abstract][Full Text] [Related]
38. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
Mahanivong C; Yu J; Huang S
Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
[TBL] [Abstract][Full Text] [Related]
39. Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor.
Høyer-Hansen G; Pessara U; Holm A; Pass J; Weidle U; Danø K; Behrendt N
Biochem J; 2001 Sep; 358(Pt 3):673-9. PubMed ID: 11535128
[TBL] [Abstract][Full Text] [Related]
40. Sequences within domain II of the urokinase receptor critical for differential ligand recognition.
Li Y; Lawrence DA; Zhang L
J Biol Chem; 2003 Aug; 278(32):29925-32. PubMed ID: 12761227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
